The angiopoietin (ANG)–TIE growth factor receptor pathway regulates pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. It has become an attractive pharmacological target for oncological and ophthalmological indications, as well as sepsis, diabetic vasculopathies, organ transplantation and atherosclerosis. Here, Alitalo and colleagues provide an overview of the biology of the ANG–TIE pathway and discuss the development of therapeutics that target it.
- Pipsa Saharinen
- Lauri Eklund
- Kari Alitalo